A Population Pharmacokinetics Model for Vancomycin Dosage Optimization Based on Serum Cystatin C
Jie-Jiu Lu1, Ming Chen1, Chun-Le Lv1
1Department of Pharmacy, The First Affiliated Hospital of Guangxi Medical University, No. 6 Shuangyong Road, Nanning, 530021, Guangxi, People's Republic of China.
European Journal of Drug Metabolism and Pharmacokinetics
|April 19, 2020
Summary
This study developed a population pharmacokinetic model for vancomycin in pediatric patients using serum cystatin C to predict renal function. Optimized vancomycin dosages were simulated to achieve target therapeutic goals.
Area of Science:
- Pharmacology
- Nephrology
- Pediatrics
Background:
- Renal function significantly impacts vancomycin pharmacokinetics.
- Serum cystatin C (CysC) is a reliable marker for assessing renal function.
- Accurate pharmacokinetic modeling is crucial for optimizing vancomycin therapy in children.
Purpose of the Study:
- To develop a population pharmacokinetic (PopPK) model for vancomycin in pediatric patients utilizing serum CysC.
- To optimize vancomycin dosage regimens based on AUC0-24/MIC targets and Css,trough.
- To establish a reference for vancomycin dosing in pediatric populations.
Main Methods:
- Retrospective data collection from pediatric patients (2-18 years) receiving vancomycin.
- Population pharmacokinetic analysis using nonlinear mixed-effects modeling (NONMEM).
- Monte Carlo simulations to evaluate dosage optimization and target attainment.
Main Results:
- Serum CysC and age were identified as significant covariates influencing vancomycin pharmacokinetics.
- The developed PopPK model estimated vancomycin clearance at 2.25 L/h and volume of distribution at 8.17 L.
- Simulations indicated probability of target attainment for AUC0-24/MIC ratios (400-700) around 66-68% across age groups, with median Css,trough values varying by age.
Conclusions:
- A vancomycin PopPK model incorporating serum CysC was successfully developed for pediatric patients.
- The study provides valuable simulated dosage recommendations for optimizing vancomycin therapy.
- This model aids in achieving desired therapeutic outcomes and minimizing toxicity in pediatric vancomycin treatment.
Related Concept Videos
01:15Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
167
Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
167
01:20Estimation of k and VD of Aminoglycosides
142
Aminoglycosides are a class of antibiotics used to treat various bacterial infections. Clinicians must determine the elimination rate constant (k) and volume of distribution (VD) to optimize therapeutic efficacy and minimize toxicity. The k value represents the rate at which the drug is removed from the body, and the VD reflects the degree to which the drug distributes into body tissues. Accurately estimating these parameters allows healthcare professionals to tailor drug dosing to individual...
142
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
150
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
150
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
96
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
96
01:25Clearance Models: Compartment Models
258
Clearance measures drug elimination from the central compartment, including plasma and highly perfused organs like kidneys and liver. Its calculation varies depending on pharmacokinetic models and administration routes. The one-compartment model, for instance, portrays the pharmacokinetics of polar drugs such as aminoglycoside antibiotics administered intravenously and readily excreted in urine. In this case, clearance is influenced by the terminal rate constant (λz) and the total volume...
258
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
149
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
149